177-181 Avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
https://www.dbv-technologies.com
Settore/i:
Settore:
Impiegati a tempo pieno: 104
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Daniel Tassé | CEO & Director | 1,12M | N/D | 1960 |
Dr. Pharis Mohideen | Chief Medical Officer | 669,44k | N/D | 1965 |
Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. | CFO & Principal Accounting Officer | N/D | N/D | 1969 |
Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer | N/D | N/D | N/D |
Ms. Michele F. Robertson | Chief Legal Officer | N/D | N/D | N/D |
Ms. Caroline Daniere | Chief Human Resources Officer & Chief of Staff | N/D | N/D | 1975 |
Dr. Wence Agbotounou | Chief Clinical Trial Officer & Senior VP | N/D | N/D | N/D |
Mr. Edward P. Jordan M.B.A. | Senior Vice President of Commercial Operations North America | N/D | N/D | 1968 |
Alan Kerr | Senior VP & Head of Global Regulatory Affairs | N/D | N/D | N/D |
Mr. Pascal Wotling | Chief External Manufacturing & Supply Chain Officer | N/D | N/D | N/D |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
L'ISS Governance QualityScore di DBV Technologies S.A. al 1 marzo 2024 è 10. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 9; diritti degli azionisti: 1; retribuzione: 10.